BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering

FRANKLIN LAKES, N.J., April 27, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global distribution of a complete portfolio of products for mass spectrometry that provides high-speed and high-confidence identification of pathogens in clinical laboratories ─ a critical first step in the fight against antimicrobial resistance.

Current trends project antimicrobial resistance could cause up to 10 millionⁱ deaths annually by 2050. Fast and accurate identification of pathogens is often the first step in addressing this issue and with a complete and seamless identification/ antimicrobial susceptibility (ID/AST) solution, BD reinforces its commitment to support hospitals and researchers globally in managing antimicrobial resistance.

By directly offering MBT Biotargets^® and MBT Sepsityper^®1, as well as standard reagents and other products, BD completes a comprehensive mass spectrometry solutions suite. MBT Biotargetsⁱⁱ are disposable plates that can be run multiple times, reducing waste. MBT Sepsityperⁱⁱⁱ, a new sepsis management kit, enables pathogen identification from positive blood cultures, eliminating the time-consuming step of culturing the micro-organisms.

"Comprehensive ID/AST solutions allow doctors and hospitals to diagnose and treat critically ill patients quickly and accurately," said Steve Conly, vice president and general manager of Microbiology for BD. "Our state-of-the-art ID/AST solution is just one way that BD helps to reduce the prevalence of antimicrobial resistance."

BD's complete portfolio offer of MALDI Biotyper products – including the MALDI Biotyper^® smart, an enhanced version of the BD Bruker MALDI Biotyper – allows health care providers to accurately and more effectively assist in diagnosing patients with infectious diseases in minutes. The seamless connectivity^iv between the BD Bruker MALDI Biotyper, the recently launched BD Phoenix M50™^v, and BD EpiCenter™^vi, a data management system, provide a comprehensive and efficient ID/AST solution for health care providers.

Visit bd.com/ds for more information.

About BD
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.

¹ MBT Biotargets and MBT Sepsityper^® are not FDA cleared, and are not currently available for sale in the U.S. For Research Use Only versions of these products are available in the U.S. and are not for use in diagnostic procedures.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bd-advances-efforts-to-combat-antimicrobial-resistance-with-enhanced-diagnostic-solution-offering-300446932.html

SOURCE BD (Becton, Dickinson and Company)